BAT1306 + BAT8001

BAT1306 + BAT8001 is a combination therapy under investigation for the treatment of HER2-positive advanced solid tumors. BAT1306 is a recombinant, humanized monoclonal antibody that targets programmed cell death protein 1 (PD-1), functioning as an immune checkpoint inhibitor to enhance T-cell mediated anti-tumor responses[2][4][7]. BAT8001 is an antibody-drug conjugate (ADC) composed of a trastuzumab biosimilar linked to a cytotoxic payload, targeting human epidermal growth factor receptor 2 (HER2)-expressing cells[3]. The combination aims to leverage both immune checkpoint blockade and targeted cytotoxicity against tumor cells. Both agents are being developed by Bio-Thera Solutions for use in oncology, particularly in HER2-positive advanced solid tumors[1][3][4][7].